Press Release
2023
2022
2021
2020
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
On October 25, 2023, during the 2023 Boehringer Ingelheim China R&D Day event, Burning Rock and Boehringer Ingelheim officially signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese...
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
GUANGZHOU, China, Oct. 15, 2023 -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its...
Burning Rock announced a China collaboration with AstraZeneca
On August 9, 2023, Burning Rock (NASDAQ/LSE: BNR) announced a China collaboration with AstraZeneca (NASDAQ/LSE/STO: AZN). As part of the collaboration, Burning Rock will leverage its leading detection technologies and high-quality, standardized testing capabilities to...
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif. Jan.03, 2023 - Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been...
Burning Rock Announces the Launch of China’s First Prospective Interventional Validation Study on Multi-Cancer Early Detection – the PREVENT Study
CHENGDU, China, June 30, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the...
Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits
IRVINE, Calif. June 1, 2022--Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that the Company had received CE mark approval for three self-developed next generation sequencing (NGS) kits, namely, “OncoScreen™ Plus Cancer Mutation...
Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit
IRVINE, Calif. June 1, 2022--Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number:...
Burning Rock Secures Second NGS Kit Approval from the NMPA
GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that the National Medical Products Administration (NMPA) approved Burning Rock’s Human Nine-Gene Mutation Joint Detection...
Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock’s OncoCompass™ Target
GUANGZHOU, China, Nov. 17, 2021– Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the...